The current treatment paradigm for patients with metastatic colorectal... | Download Scientific Diagram
Identification of actionable alterations in colorectal cancer are leading to the development of novel treatment strategies - Mayo Clinic
Frontiers | Targeting KRAS: The Elephant in the Room of Epithelial Cancers
KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy
Target Genetic Abnormalities for the Treatment of Colon Cancer and Its Progression to Metastasis | Bentham Science
Biomedicines | Free Full-Text | Identifying Novel Actionable Targets in Colon Cancer
Clinical characteristics and prognostic value of the KRAS mutation in Chinese colorectal cancer patients - Ye Yuan, Yingting Liu, Ye Wu, Junling Zhang, Chunti Shen, Feng Zhang, Changping Wu, Wenwei Hu, 2021
Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer | Semantic Scholar
IJMS | Free Full-Text | Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
Colorectal Cancer – Treatments | Gastrointestinal Cancer
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis - The Lancet Oncology
KRAS testing is a screening of non-responders to anti-EGFR therapy.... | Download Scientific Diagram
KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin‑ or irinotecan‑based treatment
Colorectal Cancer
Life | Free Full-Text | Integrated Decision-Making in the Treatment of Colon -Rectal Cancer: The Case of KRAS-Mutated Tumors
Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer | Pharmacogenomics
TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers - ScienceDirect
JCI Insight - Targeting the undruggable oncogenic KRAS: the dawn of hope
Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. | Semantic Scholar
Frontiers | Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab
The Trouble With KRAS - Cancer Commons
KRAS-Targeted Therapy Doubles as Component of Immunotherapy - NCI
